JPRN-UMIN000030806已完成1 期
A phase I/II clinical trial of hematopoietic stem cell gene therapy for Wiskott-Aldrich Syndrome - Hematopoietic stem cell gene therapy for Wiskott-Aldrich Syndrome
ational Center for Child Heath and Development0 个研究点目标入组 3 人开始时间: 2018年1月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •Patients who meet any of the following criteria will be excluded. 1. Patients positive for HIV infection 2. Patients affected by neoplasia 3. Patients with cytogenetic alterations typical of MDS/AML 4. Patients with end-organ function or any other severe disease, which, in the judgement of the investigator, would make the patients inappropriate for entry into this study 5. Patients who underwent an allogeneic hematopoietic stem cell transplantation in the previous 6 months 6. Patients who underwent an allogeneic hematopoietic stem cell transplantation with evidence of residual donor cells 7. Patients who have the possibility of severe allergic reactions, to rituximab and the products derived from cow, pig, sheep and mouse. 8. Patients who do not agree with a contraception during the trial. 9. Patients who are considered inappropriate, in the judgement of the investigator, due to any other reasons.
研究者
相似试验
招募中
2 期
Hematopoietic stem cell gene therapy study2024-515253-25-00Orchard Therapeutics (Europe) Limited20
招募中
不适用
Clinical Phase II Study of hematopoietic stem ctell transplantation for ataxia telangiectasia and related diseasesataxia telangiectasia DNA damage response disorderJPRN-UMIN000019532Graduate Schoool, Dept. of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University5
进行中（未招募）
1 期
Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome - Gene therapy for WASEUCTR2009-011152-22-FRGENETHO10
已完成
不适用
A pilot study for hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and anti-thymoglobulin from HLA-mismatched related donor for non-malignant diseases (Halo-NM)on-malignant diseases (bone marrow failure, immunodeficiency, inborn errors of metabolism)JPRN-UMIN000026159ational Center for Child Health and Development9
已完成
2 期
Phase 2 trial of autologous hematopoietic stem cell transplantation for severe systemic sclerosisSystemic sclerosisJPRN-UMIN000031940Kyushu University24